Impact of abciximab versus tirofiban on hospital length of stay for PCI patients

Catheterization and Cardiovascular Interventions

Volumn 52, Issue 3, 2001, Pages 298-305

  Lage, Maureen J ^a   Barber, Beth L ^b   McCollam, Patrick L ^b   Bala, Mohan ^c   Scherer, Joel ^b  

^a MIAMI UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CENTOCOR INC   (United States)

Author keywords

Hospital stay; Length of stay; Multivariate analysis; Retrospective study; Sample selection model

Indexed keywords

ABCIXIMAB; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PENNSYLVANIA; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TYROSINE;

EID: 0035120456     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1069     Document Type: Article

References (39)

1. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary sapheneous vein grafts
2. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal Antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
3. An overview of the results of the EPIC trial
4. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention
5. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
6. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective
7. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade
8. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
9. Economic impact of GPIIb/IIIa blockade after high-risk angioplasty: Results from the RESTORE trial
10. Effects of platelet GPIIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
11. Care of acute myocardial infarction by non-invasive and invasive cardiologists: Procedure use, cost and outcome
12. The relationship between hospital length of stay and rate of death in heart failures
13. Hospital discharge decisions, health outcomes, and the use of unobserved information on case-mix severity
14. The hospital course and short term prognosis of patients presenting to the emergency room with decompensated congestive heart failure
15. Early readmission of elderly patients with congestive heart failure
16. Issues in the analysis of selectivity bias
17. Generalized models with selectivity
18. Sample selection as a specification error
19. Health care costs and outcomes: How should we evaluate real world data?
20. Estimating endogenous treatment effects in retrospective data analysis
21. Methods for using large databases in health care research: Problems and promises - Proceedings of the Third Biennial Regenstrief Conference
22. SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: Evidence from primary care in the United Kingdom
23. Length of hospital stay after acute myocardial infarction in the myocardial infarction triage and intervention (MITI) project registry
24. Comorbidity as a correlate of length of stay for hospitalized patients with acute chest pain
25. Analyzing intensive care unit length of stay data: Problems and possible solutions
26. Refinement of the medicare diagnosis-related groups to incorporate a measure of severity
27. Timeliness and quality of care for elderly patients with acute myocardial infarction under health maintenance organization vs fee for service insurance
28. Shorter hospital stays for angioplasty patients who receive abciximab
29. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states
30. Regional variation across the United States in the management of acute myocardial infarction
31. Cardiology and the quality of medical practice
32. Economic issues in glycoprotein IIb/IIIa receptor therapy
33. Anaysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes
34. The association of hospital volumes of percutaneous transluminal coronary angioplasty with adverse outcomes, length of stay, and charges in California
35. The effect of complications on length of stay
36. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables
37. A statistical model for the analysis of ordinal level dependent variables